1. P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL. (23rd June 2022) Authors: Zinzani, P. L.; Özcan, M.; Sapunarova, K.; Jurczak, W.; Hamed, A.; Bouabdallah, K.; Saydam, G.; Geissler, K.; Szomor, Á.; Lazaroiu, M.; Salar, A.; Tempescul, A.; Nalcaci, M.; Gercheva, L.; Egyed, M.; Panayiotidis, P.; Mongay Soler, L.; Cao, A.; Phelps, C.; H Childs, B. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1028 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗